Loading... Please wait...
Sort by:

 

FirstView NPS+

An expanded view of brand loyalty among doctors

Actionable metrics to help you make better brand decisions

 

Net Promoter Score (NPS) is an easy way to measure brand health, but it doesn’t tell you how to improve it. NPS+ turns your Net Promoter Score into actionable information by answering key questions about brand loyalty

 

Each NPS+ report examines doctors’ relationships with the brands used to treat a major disease area—measuring brand loyalty and showing you how it affects your market share. NPS+ also examines “brand DNA”, revealing in doctors’ own words what brands mean to them.

 

Instead of one simple metric, NPS+ gives you a detailed picture of brand health that highlights areas for improvement, and helps you see exactly what steps you need to take next.

  • Pages:
  • 1
  • 2
  • NPS+ HIV (US) 2017
    Learn More NPS+ HIV (US) 2017
    Doctors upbeat about HIV treatments, but satisfaction runs highest for 3 brands Doctors may be satisfied with available HIV treatments overall, but when we surveyed 100 US-based infectious disease specialists and...
  • NPS+ HIV (EU5) 2017
    Learn More NPS+ HIV (EU5) 2017
    Doctors upbeat about HIV treatments, but satisfaction runs highest for 2 brands Doctors may be satisfied with available HIV treatments overall, but when we surveyed 150 EU5-based infectious disease specialists and...
  • NPS+ Renal Cell Carcinoma (EU5) 2017
    Learn More NPS+ Renal Cell Carcinoma (EU5) 2017
    How ‘healthy’ are brand loyalty and satisfaction levels amongst RCC oncologists? According to this latest survey, the top three ‘healthiest’ Renal Cell Carcinoma (RCC) brands in Europe with the...
  • NPS+ Renal Cell Carcinoma (US) 2017
    Learn More NPS+ Renal Cell Carcinoma (US) 2017
    How ‘healthy’ are brand loyalty and satisfaction levels amongst RCC oncologists? With some relatively recent entrants gaining ground amongst a field of established drugs, how is brand loyalty faring across...
  • NPS+ Parkinson’s Disease (EU5) 2017
    Learn More NPS+ Parkinson’s Disease (EU5) 2017
    Low scores for 7 of 8 surveyed brands reflect widespread dissatisfaction among doctors Neurologists in the EU5 countries are not happy with available Parkinson’s disease treatments, and it shows. According to our...
  • NPS+ Parkinson’s Disease (US) 2017
    Learn More NPS+ Parkinson’s Disease (US) 2017
    Only three drugs get positive satisfaction scores from neurologists. Is your brand one of them? US neurologists are satisfied with available Parkinson’s disease treatments, but that doesn’t mean...
  • NPS+ Cancer Pain (EU5) 2017
    Learn More NPS+ Cancer Pain (EU5) 2017
    Only three drugs get positive satisfaction scores from oncologists. Is your brand one of them? In our survey of ten cancer pain drugs, only three brands earned positive satisfaction scores from doctors in the EU5...
  • NPS+ Cancer Pain (US) 2017
    Learn More NPS+ Cancer Pain (US) 2017
    Top brand has an insurmountable lead. Can your brand narrow the gap? In our survey of 11 cancer pain drugs, only one brand earned a positive satisfaction score from US doctors. The runaway favourite, this brand is...
  • NPS+ Multiple Myeloma (EU5) 2016
    Learn More NPS+ Multiple Myeloma (EU5) 2016
    Two brands are way out front in an otherwise unsatisfied market. Where does your brand rank? According to our survey of 150 medical oncologists and haematologists, doctors in the EU5 countries are not happy with available...
  • NPS+ Multiple Myeloma (US) 2016
    Learn More NPS+ Multiple Myeloma (US) 2016
    Overall satisfaction is high, but three brands are way ahead. Can your brand catch up? Our survey of 100 medical oncologists and haematologists shows that while US doctors are happy with available myeloma therapies, some...
  • NPS+ Multiple Sclerosis (EU5) 2016
    Learn More NPS+ Multiple Sclerosis (EU5) 2016
    One brand comes out ahead as low satisfaction scores plague MS therapies. Is your brand far behind? Multiple Sclerosis (MS) therapies have a big perception problem in the EU5 countries. Nearly half of the doctors we...
  • NPS+ Multiple Sclerosis (US) 2016
    Learn More NPS+ Multiple Sclerosis (US) 2016
    One brand comes out ahead as low satisfaction scores plague MS therapies. Is your brand far behind? Multiple Sclerosis (MS) therapies have a big perception problem. Over a third of the doctors we surveyed are unhappy with...
  • NPS+ Type 2 Diabetes Mellitus (EU) 2016
    Learn More NPS+ Type 2 Diabetes Mellitus (EU) 2016
    Which brands are edging ahead of the rest in the brand satisfaction stakes?  The EU market for Type 2 Diabetes Mellitus (T2DM) drugs has plenty of contenders – but which brands are the healthiest? What are the...
  • NPS+ Type 2 Diabetes Mellitus (US) 2016
    Learn More NPS+ Type 2 Diabetes Mellitus (US) 2016
    Which brands are edging ahead of the rest in the brand satisfaction stakes?  The US market for Type 2 Diabetes Mellitus (T2DM) drugs has plenty of contenders – but which brands are the healthiest? What are the...
  • NPS+ Rheumatoid Arthritis (EU5)
    Learn More NPS+ Rheumatoid Arthritis (EU5)
    Two leading brands continue to dominate satisfaction scores. Where does your brand rank? Few brands are earning high satisfaction scores in the European rheumatoid arthritis (RA) treatment market, but two long-time leaders...
  • NPS+ Rheumatoid Arthritis (US)
    Learn More NPS+ Rheumatoid Arthritis (US)
    Satisfaction survey results: Top 2 brands are way ahead of the pack. Can your brand close the gap? In the US rheumatoid arthritis (RA) treatment market, the two leading brands are trouncing the competition, earning far and...
  • NPS+ Growth Hormone Deficiency (EU5)
    Learn More NPS+ Growth Hormone Deficiency (EU5)
    Just one brand shows a positive Net Promoter Score in the EU: fertile ground for other brands to gain share? EU endocrinologists are not overly satisfied with current growth hormone deficiency treatment options, with only...
  • NPS+ Growth Hormone Deficiency (US)
    Learn More NPS+ Growth Hormone Deficiency (US)
    Could differentiation efforts boost some GHD brands in the US? Opportunity lurks in the US Growth hormone Deficiency treatment landscape. Although 3 established brands dominate, promoters of these brands are starting to...
  • NPS+ Non-Small Cell Lung Cancer (NSCLC) (US)
    Learn More NPS+ Non-Small Cell Lung Cancer (NSCLC) (US)
    In our satisfaction survey, one drug leaves the rest in the dust. How does your brand compare? We interviewed 100 US oncologists to find out how satisfied they are with non-small cell lung cancer (NSCLC) drugs. Which brand...
  • NPS+ Non-Small Cell Lung Cancer (NSCLC) (EU5)
    Learn More NPS+ Non-Small Cell Lung Cancer (NSCLC) (EU5)
    The race for 2nd place is on as one drug takes an impressive lead. Where does your brand rank? We interviewed 150 European oncologists to find out how satisfied they are with non-small cell lung cancer (NSCLC) drugs...
  • Pages:
  • 1
  • 2

customer.service@firstwordpharma.com

All Contents Copyright © 2017 Doctor's Guide Publishing Limited All Rights Reserved